# Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

> **NCT04729608** · PHASE3 · TERMINATED · sponsor: **Aravive, Inc.** · enrollment: 366 (actual)

## Conditions studied

- Platinum-resistant Ovarian Cancer

## Interventions

- **DRUG:** Batiraxcept
- **DRUG:** Paclitaxel
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04729608
- **Lead sponsor:** Aravive, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-22
- **Primary completion:** 2023-08-04
- **Final completion:** 2023-08-04
- **Target enrollment:** 366 (ACTUAL)
- **Why stopped:** There were no significant differences in median PFS between batiraxcept + paclitaxel or paclitaxel alone arms. There was no detriment to overall survival. No new safety signals were identified.
- **Last updated:** 2023-10-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04729608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04729608, "Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT04729608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*